Abstract C041: Safety and pharmacokinetic results from a phase 1, multicenter, open-label study of [fam-] trastuzumab deruxtecan (T-DXd; DS-8201a) in subjects with advanced HER2-positive breast cancer
Sign Up to like & getrecommendations! Published in 2019 at "Molecular Cancer Therapeutics"
DOI: 10.1158/1535-7163.targ-19-c041
Abstract: Background: Anti-HER2 therapies are beneficial for patients with HER2+ gastric or breast cancer (BC). [Fam-] trastuzumab deruxtecan (T-DXd; formerly DS-8201a) is an antibody-drug conjugate (ADC) composed of an anti-HER2 antibody (Ab) conjugated by a peptide-based… read more here.
Keywords: dxd; study; breast cancer; fam trastuzumab ... See more keywords
Metastatic Parotid Gland Carcinoma With ERBB2 Amplification With Complete Response to Fam-Trastuzumab Deruxtecan.
Sign Up to like & getrecommendations! Published in 2022 at "Journal of the National Comprehensive Cancer Network : JNCCN"
DOI: 10.6004/jnccn.2021.7089
Abstract: HER2 mutations have been shown to be targetable in select cases of salivary gland cancers with overexpression or amplification of the HER2 oncogene. Fam-trastuzumab deruxtecan, a novel antibody-drug conjugate that combines trastuzumab with a topoisomerase… read more here.
Keywords: fam trastuzumab; her2; gland; gland carcinoma ... See more keywords